Zymeworks (NASDAQ:ZYME) Shareholders Are up 9.5% This Past Week, but Still in the Red Over the Last Three Years
Zymeworks Inc. (NASDAQ:ZYME) shareholders should be happy to see the share price up 19% in the last month. But that doesn't change the fact that the returns over the last three years have been
Zymeworks to Unveil Q2 2024 Results and Drug Progress
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the
H.C. Wainwright Maintains Zymeworks(ZYME.US) With Hold Rating, Maintains Target Price $10
H.C. Wainwright analyst Robert Burns maintains $Zymeworks(ZYME.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 24.0% and a
Zymeworks Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 17.1% HC Wainwright & Co. $10 → $10 Reiterates Buy → Buy 06/06/2024 17.1% HC Wainwright & Co. $
Zymeworks ZW171 IND for Mesothelin-expressing Cancers Cleared by FDA
Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy
Zymeworks (ZYME) said on Monday that the US Food and Drug Administration has cleared the investigational new drug application for its experimental therapy, ZW171, to treat mesothelin-expressing cancer
Market-Moving News for June 17th
BBY: 4% | UBS Upgrades Best Buy Co to Buy, Raises Price Target to $106ZYME: 13% | Zymeworks shares are trading higher after the FDA cleared the company's Investigational New Drug application for Zw171
Express News | Zymeworks Shares Are Trading Higher After the FDA Cleared the Company's Investigational New Drug Application for Zw171 for Mesothelin-expressing Cancers, With the Company Expecting to Initiate Clinical Development During 2024
Express News | Zymeworks Shares up 4.1% Premarket After FDA Clears Co's Application to Start Trials in Humans for Cancer Drug
Express News | FDA Clears Zymeworks' Investigational New Drug Application For Zw171 For Mesothelin-expressing Cancers, The Company Expects To Initiate Clinical Development Of Zw171 During 2024
Express News | Zymeworks: To File Applications Seeking Regulatory Permission to Commence Clinical Studies for ZW171 in Other Non-US Jurisdictions in H2 2024
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a Novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
The Company expects to file applications seeking regulatory permission to commence clinical studies for ZW171 in other non-US jurisdictions in the second half of 2024.
Express News | Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a Novel 2+1 T-Cell Targeting Bispecific Antibody for Mesothelin-Expressing Cancers
Zymeworks (NASDAQ:ZYME) Investors Are Sitting on a Loss of 75% If They Invested Three Years Ago
Subdued Growth No Barrier To Zymeworks Inc.'s (NASDAQ:ZYME) Price
It's not a stretch to say that Zymeworks Inc.'s (NASDAQ:ZYME) price-to-sales (or "P/S") ratio of 13.6x right now seems quite "middle-of-the-road" for companies in the Biotechs industry in the United
Form 144 | Zymeworks(ZYME.US) Insider Proposes to Sell 774.06K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 11, $Zymeworks(ZYME.US)$ Insider Christopher Astle intends to sell 86,294 shares of its common stock on Jun 11, with a total market value of approximately $774.06K. Sour
Sector Update: Health Care Stocks Decline Premarket Monday
Health care stocks were declining premarket Monday as the iShares Biotechnology ETF (IBB) was 0.5% lower and the Health Care Select Sector SPDR Fund (XLV) was down 0.3% recently. Skye Bioscience (SKYE
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy
Zymeworks (ZYME) said Monday that China's health regulator has accepted the Biologics License Application for its second-line experimental treatment of HER2-positive biliary tract cancer, zanidatamab.
Zymeworks' BLA For Zanidatamab For HER2-positive BTC Accepted By CDE In China